Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval

Pharma To Carve HCC Niche On Survival Data

Executive Summary

More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.

You may also be interested in...



Etranacogene Dezaparvovec, Omburtamab & Tremelimumab Await EMA Verdict

Four of the six products up for a marketing authorization opinion from the EMA’s advisory committee, the CHMP, this week are orphan drugs. One of them, omburtamab, was recently turned down by a US FDA advisory panel.

AstraZeneca Confident About Evusheld's Future Growth

Now approved for the treatment as well as the prevention of COVID-19 in the EU and Japan, the UK major’s antibody combo passed the $500m sales barrier in the third quarter and CEO Pascal Soriot is confident that growth will continue.

Keeping Track: AZ’s Imjudo, J&J’s Tecvayli Enter Burgeoning Immuno-Oncology Market; Genmab Submits Epcoritamab

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel